A Safety and Efficacy Study of Xolair in Peanut Allergy
Part of paid clinical trials in Denver, Colorado.
- Sponsor
- Genentech, Inc.
- Study ID
- NCT00086606
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Allergy
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Xolair (omalizumab) — DRUG
Study Details
This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.
Key Dates
- Start date
- Jun 30, 2004
- Status verified
- Jan 2013
- Completion
- Apr 30, 2006
Study Design
- Enrollment
- 150 participants
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Trial Information Support Line | Denver | Colorado | 80012 | - |
Find similar trials in Denver, CO
By research site
Related Studies
- Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)PHASE3 · Recruiting · DBV Technologies · Birmingham, Alabama
- Understanding Allergies and Sensitizations in Healthy and Allergic IndividualsRecruiting · Stanford University · Palo Alto, California
- Study of Oral Food Challenge Biomarkers (SAFER)Not Yet Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas
- LYmph Node eXamination in Cat Allergen ImmunotherapyEARLY_PHASE1 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Boston, Massachusetts